propranolol indications/contra

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 2303 525-66-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propranolol
  • betalong
  • DL-Propranolol
  • racemic propranolol
  • beta-Propranolol
  • propranolol hydrochloride
  • hemangiol
  • propranolol HCl
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
  • Molecular weight: 259.35
  • Formula: C16H21NO2
  • CLOGP: 2.75
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.49
  • ALOGS: -3.51
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.16 g O
0.16 g P

Approvals:

DateAgencyCompanyOrphan
Nov. 13, 1967 FDA BAXTER HLTHCARE CORP

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 2044.99 37.13 542 3106 30572 3351639
Toxicity to various agents 1336.88 37.13 429 3219 46625 3335586
Bradycardia 1068.86 37.13 287 3361 16382 3365829
Cardiac arrest 984.37 37.13 300 3348 27019 3355192
Hypotension 945.24 37.13 336 3312 49178 3333033
Overdose 779.01 37.13 265 3383 33713 3348498
Cardio-respiratory arrest 521.17 37.13 162 3486 15278 3366933
Intentional overdose 514.95 37.13 160 3488 15065 3367146
Respiratory arrest 494.08 37.13 145 3503 11223 3370988
Hypoglycaemia 448.56 37.13 142 3506 14176 3368035
Cardiogenic shock 324.92 37.13 83 3565 3783 3378428
Drug interaction 300.34 37.13 147 3501 46665 3335546
Circulatory collapse 279.19 37.13 81 3567 5968 3376243
Off label use 249.38 37.13 136 3512 53841 3328370
Sinus bradycardia 237.64 37.13 63 3585 3316 3378895
Drug administered to patient of inappropriate age 237.47 37.13 52 3596 1200 3381011
Heart rate decreased 227.27 37.13 67 3581 5211 3377000
Seizure 220.89 37.13 114 3534 40286 3341925
Poisoning 203.14 37.13 61 3587 5051 3377160
Peripheral coldness 200.15 37.13 51 3597 2291 3379920
Unresponsive to stimuli 180.11 37.13 62 3586 7946 3374265
Depressed level of consciousness 169.08 37.13 65 3583 11400 3370811
Blood pressure decreased 167.48 37.13 68 3580 13768 3368443
Coma 166.86 37.13 66 3582 12486 3369725
Pulseless electrical activity 166.27 37.13 41 3607 1607 3380604
Hypoglycaemic seizure 155.49 37.13 28 3620 222 3381989
Drug hypersensitivity 153.60 37.13 86 3562 35594 3346617
Death 150.60 37.13 151 3497 152173 3230038
Suicide attempt 148.73 37.13 65 3583 15782 3366429
Electrocardiogram QRS complex prolonged 148.56 37.13 36 3612 1310 3380901

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC C07AA05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07BA05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, non-selective, and thiazides
ATC C07FX01 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35530 beta-adrenergic antagonist
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:35620 vasodilator agent
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Supraventricular tachycardia indication 6456007
Hypertensive disorder indication 38341003 DOID:10763
Atrial fibrillation indication 49436004 DOID:0060224
Angina pectoris indication 194828000
Hypertrophic cardiomyopathy indication 233873004 DOID:11984
Idiopathic hypertrophic subaortic stenosis indication 360465008
Hemangioma indication 400210000 DOID:255
Essential tremor indication 609558009 DOID:4990
Migraine Prevention indication
Life-Threatening Ventricular Tachycardia indication
Myocardial Reinfarction Prevention indication
Arrhythmias During Surgery indication
Pheochromocytoma Adjunct Therapy indication
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Secondary angle-closure glaucoma contraindication 21571006
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007 DOID:2848
Hyperuricemia contraindication 35885006 DOID:1920
Sick sinus syndrome contraindication 36083008 DOID:13884
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Chronic bronchitis contraindication 63480004 DOID:6132
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:2527
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of muscle contraindication 129565002 DOID:423
Hypomagnesemia contraindication 190855004
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007 DOID:9993
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Azotemia contraindication 445009001
Smokes tobacco daily contraindication 449868002
Thyrotoxicosis off-label use 90739004 DOID:7997
Mitral valve prolapse off-label use 409712001 DOID:988
Prevention of Bleeding Esophageal Varices off-label use
Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation off-label use
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.28MG/ML HEMANGEOL PIERRE FABRE DERMA N205410 March 14, 2014 RX SOLUTION ORAL 8338489 Oct. 16, 2028 METHOD TO TREAT HEMANGIOMA.

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
4.28MG/ML HEMANGEOL PIERRE FABRE DERMA N205410 March 14, 2014 RX SOLUTION ORAL March 14, 2021 TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 8.25 WOMBAT-PK DRUG LABEL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 8.71 WOMBAT-PK DRUG LABEL
5-hydroxytryptamine receptor 1B GPCR Ki 6.20 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.35 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 6.91 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.92 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.69 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.66 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.92 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.70 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX
Multidrug resistance protein 1 Transporter Ki 4.32 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.20 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.30 WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel Ki 4.32 WOMBAT-PK
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 6.22 WOMBAT-PK
Histamine H1 receptor GPCR Ki 4.70 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 5.38 PDSP
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.67 DRUG MATRIX
Beta-2 adrenergic receptor GPCR Kd 9.05 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.30 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 7.77 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 7.05 CHEMBL
D(2) dopamine receptor GPCR Ki 4.89 CHEMBL
Adrenergic receptor beta GPCR Ki 8.62 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 8.52 CHEMBL
Beta-2 adrenergic receptor GPCR Kd 9.01 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 8.76 CHEMBL
Beta-3 adrenergic receptor Unclassified ANTAGONIST Ki 6.60 IUPHAR

External reference:

scroll-->
IDSource
DB00571 DRUGBANK_ID
564 IUPHAR_LIGAND_ID
4019916 VUID
N0000148001 NUI
C0033497 UMLSCUI
D00483 KEGG_DRUG
CHEMBL27 ChEMBL_ID
4946 PUBCHEM_CID
4019916 VANDF
8787 RXNORM
372772003 SNOMEDCT_US
55745002 SNOMEDCT_US
d00032 MMSL
N0000006760 NDFRT
N0000148001 NDFRT
004740 NDDF
9Y8NXQ24VQ UNII
1940 INN_ID
CHEBI:8499 CHEBI
CHEMBL1671 ChEMBL_ID
D011433 MESH_DESCRIPTOR_UI
318-98-9 SECONDARY_CAS_RN
SNP PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3727 SOLUTION 20 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3730 SOLUTION 40 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1659 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1660 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1661 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1662 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1693 TABLET 60 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9872 INJECTION 1 mg INTRAVENOUS ANDA 13 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2778 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2779 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2780 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2781 CAPSULE, EXTENDED RELEASE 160 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0084 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0085 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0086 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0087 CAPSULE, EXTENDED RELEASE 160 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0182 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0183 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0184 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0185 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0187 TABLET 60 mg ORAL ANDA 11 sections
Propranolol Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0347 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0731 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5554 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5555 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5556 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5557 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5482 TABLET 10 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5483 TABLET 20 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5484 TABLET 40 mg ORAL ANDA 14 sections